secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000318154-24-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q2 2024 revenue up 20% to $8.4B, but GAAP EPS falls 46% to $1.38
----------------------------------------------------------------------

- Total revenues $8.4B, up 20% YoY; product sales up 20% (5% ex-Horizon), driven by 26% volume growth.
- GAAP EPS $1.38 (down 46%); non-GAAP EPS $4.97 (down 1%); GAAP operating margin 23.7% vs 40.2%.
- Free cash flow $2.2B, vs $3.8B in Q2 2023, due to timing of tax payments.
- Twelve products had double-digit sales growth; rare disease sales $1.1B; Repatha, Prolia, TEZSPIRE among leaders.
- Non-GAAP operating income $3.9B (up 11%); operating margin 48.2%, down 4.4pp year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815424000033/0000318154-24-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815424000033/amgn-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000318154-24-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer